Market Analysis on Late Stage Chronic Kidney Disease Drugs Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Late Stage Chronic Kidney Disease Drugs Market from 2024 to 2025?
The market size for drugs used in treating late stage chronic kidney disease has experienced a swift growth recently. The market is set to expand from $7.08 billion in 2024 to $7.92 billion in 2025, representing a compound annual growth rate (CAGR) of 11.9%. The rising growth during the historic period can be accounted to factors such as enhanced diagnostic capabilities, a rise in aging demographics, increasing incidents of diabetes and hypertension, amplified consciousness about kidney diseases, and the expansion in pharmaceutical research and development efforts.
What Is the Projected Market Size of the Late Stage Chronic Kidney Disease Drugs Market?
In the forthcoming years, the market for late stage chronic kidney disease medications is projected to experience a swift expansion. The market is predicted to reach a size of $12.2 billion by 2029, with a compound annual growth rate (CAGR) of 11.4%. This growth could be ascribed to several factors in the forecast period, such as a surge in healthcare spending, adoption of precision medicine strategies, an increased focus on regenerative medicine, greater emphasis on patient-centric care, and worldwide initiatives to raise awareness about kidney disease. Notable trends of the forecast period comprise the enlargement of regenerative medicine therapies, rise in the use of telemedicine services for CKD management, development of combination therapies, emphasis on early intervention tactics, and a growing interest in the use of biomarker-based diagnostics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
Who are the Major Competitors in the Late Stage Chronic Kidney Disease Drugs Market Outlook?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
What Is Fueling Growth in the Late Stage Chronic Kidney Disease Drugs Market?
The proliferation of chronic kidney diseases is set to be a significant driver for the late-stage chronic kidney disease drug market’s expansion. Chronic kidney diseases denote a vast array of conditions affecting the kidneys’ structure and functionality. Drugs developed for late-stage chronic kidney disease aim to manage blood pressure in patients, minimize protein loss, impede the advance of kidney damage, manage symptoms, and prevent possible repercussions. For example, the Centers for Disease Control and Prevention (CDC), a US-based public health organization, reported in May 2024 that an estimated 14% of U.S. adults, equating to about 35.5 million individuals, are likely to have chronic kidney diseases. Therefore, the high occurrence of chronic kidney disease is fueling the growth of the late-stage chronic kidney disease drug market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12196&type=smp
Which Late Stage Chronic Kidney Disease Drugs Market Segments Are Growing the Fastest?
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
Which Industry Trends Are Shaping the Future of the Late Stage Chronic Kidney Disease Drugs Market?
The trend of product innovation is becoming increasingly prominent within the late-stage chronic kidney disease drug market. To maintain their market positions, leading companies are focusing on the development of novel drug products. For example, in February 2022, Bayer, a German pharmaceutical and biotechnology firm, introduced Kerendia (finerenone) in the Indian market. This first-of-its-kind non-steroidal, selective mineralocorticoid receptor antagonist, known as finerenone, is advised for use by patients suffering from type two diabetes and chronic kidney disease. Its mechanism works to inhibit the excessive activation of the mineralocorticoid receptor (MR), which is believed to be a major contributor towards the progression of chronic kidney disease (CKD) and potential cardiovascular damage.
Access The Full Report Here:
Which Countries Are Leading the Late Stage Chronic Kidney Disease Drugs Market?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12196
This Report Delivers Insight On:
1. How big is the late stage chronic kidney disease drugs market, and how is it changing globally?
2. Who are the major companies in the late stage chronic kidney disease drugs market, and how are they performing?
3. What are the key opportunities and risks in the late stage chronic kidney disease drugs market right now?
4. Which products or customer segments are growing the most in the late stage chronic kidney disease drugs market?
5. What factors are helping or slowing down the growth of the late stage chronic kidney disease drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
